The cardiovascular safety profile of renzapride, a novel treatment for irritable bowel syndrome

Journal of International Medical Research

Volumn 35, Issue 6, 2007, Pages 848-866

  Meyers, Nicholas L ^a   Hickling, R I ^a  

^a Alizyme Therapeutics Limited   (United Kingdom)

Author keywords

Action potential; Benzamide; Cardiovascular safety; Cisparide; Clinical study; Healthy volunteers; Irritable bowel syndome; Renzapride

Indexed keywords

CISAPRIDE; MOXIFLOXACIN; PLACEBO; POTASSIUM CHANNEL HERG; RENZAPRIDE;

ABDOMINAL PAIN; ABNORMAL SENSATION; ADULT; ANIMAL CELL; ARTICLE; BODY TEMPERATURE; CARDIOVASCULAR RISK; CELL STRAIN HEK293; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DRUG DOSE COMPARISON; DRUG INDUCED HEADACHE; DRUG SAFETY; ELECTROCARDIOGRAPHY; FEMALE; GENE EXPRESSION; HEART MUSCLE POTENTIAL; HEART REPOLARIZATION; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IN VITRO STUDY; INTESTINE SOUND; IRRITABLE COLON; MALE; NAUSEA; NONHUMAN; NORMAL HUMAN; PULSE RATE; PURKINJE FIBER; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; SHEEP; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; VOLUNTEER;

EID: 36949024233     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323000703500613     Document Type: Article

References (54)

1. Blondel O, Gastineau M, Dahmoune Y, et al: Cloning, expression, and pharmacology of four human 5-hydroxytryptamine 4 receptor isoforms produced by alternative splicing in the carboxyl terminus. J Neurochem 1998; 70: 2252-2261.
2. 4) positively coupled to adenylate cyclase in neurons. Naunyn Schmiedebergs Arch Pharmacol 1989; 340: 403-410.
3. Mialet J, Berque-Bestel I, Sicsic S, et al: Pharmacological characterization of the human 5-HT(4(d)) receptor splice variant stably expressed in Chinese hamster ovary cells. Br J Pharmacol 2000; 131: 827-835.
4. Mialet J, Berque-Bestel I, Eftekhari P, et al: Isolation of the serotoninergic 5-HT4(e) receptor from human heart and comparative analysis of its pharmacological profile in C6-glial and CHO cell lines. Br J Pharmacol 2000; 129: 771-781.
5. 3 receptor. Pharmacol Res 1999; 39: 375-382.
6. Sanger GJ: Increased gut cholinergic activity and antagonism of 5-hydroxytryptamine M-receptors by BRL 24924: potential clinical importance of BRL 24924. Br J Pharmacol 1987; 91: 77-87.
7. 3 receptor blockade. Eur J Pharmacol 1990; 187: 323-329.
8. Song CW, Lee KY, Kim CD, et al: Effect of cisapride and renzapride on gastrointestinal motility and plasma motilin concentration in dogs. J Pharmacol Exp Ther 1997; 281: 1312-1316.
9. Dunbar AW, McClelland CM, Sanger GJ: BRL 24924: a stimulant of gut motility which is also a potent antagonist of the Bezold - Jarisch reflex in anaesthetised rats. Br J Pharmacol 1986; 88: 319P.
10. Cooper SM, McClelland CM, McRichie B, et al: BRL 24924: a new and potent gastric motility stimulant. Br J Pharmacol 1986; 88: 383P.
11. Bermudez J, Dunbar A, Sanger GJ, et al: Stimulation of canine gastric motility by BRL 24924, a new gastric prokinetic agent. J Gastrointest Motil 1990; 2: 281-286.
12. Gullikson GW, Loeffler RF, Virina MA: Relationship of serotonin-3 receptor antagonist activity to gastric emptying and motor-stimulating actions of prokinetic drugs in dogs. J Pharmacol Exp Ther 1991; 258: 103-110.
13. Meyers NL, Palmer RMJ, Wray HA, et al: Effects of single oral doses of renzapride on gastrointestinal motility in fasted healthy subjects. Gut 2002; 51(SIII): A137.
14. Meyers NL, Tack J, Middleton SJ, et al: Efficacy and safety of renzapride in patients with constipation-predominant irritable bowel syndrome. Gut 2002; 51(SIII): A10.
15. Staniforth DH, Pennick M: Human pharmacology of renzapride: a new gastrokinetic benzamide without dopamine antagonist properties. Eur J Clin Pharmacol 1990; 38: 161-164.
16. Camilleri M, McKinzie S, Fox J, et al: Effect of renzapride on transit in constipation-predominant irritable bowel syndrome. Clin Gastroenterol Hepatol 2004; 2: 895-904.
17. George A, Meyers NL, Palmer RMJ: Efficacy and safety of renzapride in constipation-predominant IBS: a phase IIB study in the UK primary healthcare setting. Gut 2003; 52(SVI): A91.
18. Wiseman LR, Faulds D: Cisapride. An updated review of its pharmacology and therapeutic efficacy as a prokinetic agent in gastrointestinal motility disorders. Drugs 1994; 47: 116-152.
19. 4 recognition sites in the porcine caudate nucleus by radioligand binding. Neuropharmacology 1994; 33: 543-549.
20. Briejer MR, Akkermans LM, Schuurkes JA: Gastrointestinal prokinetic benzamides: the pharmacology underlying stimulation of motility. Pharmacol Rev 1995; 47: 631-651.
21. Center for Drug Evaluation and Research: Cisapride marketing to be halted. News Along the Pike 2000; 6: 8. www.fda.gov/cder/ pike/mar2000.pdf (last accessed 5 October 2007)
22. Bran S, Murray WA, Hirsch IB, et al: Long QT syndrome during high-dose cisapride. Arch Intern Med 1995; 155: 765-768.
23. Ahmad SR, Wolfe SM: Cisapride and torsade de pointes. Lancet 1995; 345: 508.
24. Bedford TA, Rowbotham DJ: Cisapride. Drug interactions of clinical significance. Drug Saf 1996; 15: 167-175.
25. Hoover CA, Carmichael JK, Nolan PE Jr, et al: Cardiac arrest associated with combination cisapride and itraconazole therapy. J Cardiovasc Pharmacol Ther 1996; 1: 255-258.
26. Desta Z, Soukhova N, Mahal SK, et al: Interaction of cisapride with the human cytochrome P450 system: metabolism and inhibition studies. Drug Metab Dispos 2000; 28: 789-800.
27. Bohets H, Lavrijsen K, Hendrickx J, et al: Identification of the cytochrome P450 enzymes involved in the metabolism of cisapride: in vitro studies of potential co-medication interactions. Br J Pharmacol 2000; 129: 1655-1667.
28. Puisieux FL, Adamantidis MM, Dumotier BM, et al: Cisapride-induced prolongation of cardiac action potential and early afterdepolarizations in rabbit Purkinje fibres. Br J Pharmacol 1996; 117: 1377-1379.
29. + channel by the gastrointestinal prokinetic agent cisapride. Am J Physiol 1997; 273: H2534- H2538.
30. Rampe D, Roy ML, Dennis A, et al: A mechanism for the proarrhythmic effects of cisapride (Propulsid): high affinity blockade of the human cardiac potassium channel HERG. FEBS Lett 1997; 417: 28-32.
31. Sanguinetti MC, Jiang C, Curran ME, et al: A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel. Cell 1995; 81: 299-307.
32. Curran ME, Splawski I, Timothy KW, et al: A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell 1995; 80: 795-803.
33. Colatsky TJ, Argentieri TM: Potassium channel blockers as antiarrhythmic drugs. Drug Der Res 1994; 33: 235-249.
34. International Conference on Hormonization Harmonized Tripartite Guideline: The non-clinical evaluation of the potential for delayed ventricular repolarisation (QT interval prolongation) by human pharmaceuticals. S7B. Current Step 4 version, May 2005. http://www.ich.org/cache/compo/276-254-1.html (last accessed 5 October 2007).
35. International Conference on Harmonization Harmonized Tripartite Guideline: The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. E14. Current Step 4 version, May 2005. http://www.ich.org/cache/compo/276-254-1.html (last accessed 5 October 2007).
36. Desai M, Li L, Desta Z, et al: Variability of heart rate correction methods for the QT interval. Br J Clin Pharmacol 2003; 55: 511-517.
37. Malik M, Farbom P, Batchvarov V, et al: Relation between QT and RR intervals is highly individual among healthy subjects: implications for heart rate correction of the QT interval. Heart 2002; 87: 220-228.
38. Fridericia LS: Die systolendauer im Electrokardiogramm bei normalen Menchen und bei Herxkranken. Acta Med Scand 2002; 53: 469-486.
39. Bazett HC: An analysis of the time-relations of electrocardiograms. Heart 1920; 87: 220-228.
40. Zhou Z, Gong Q, Ye B, et al: Properties of HERG channels stably expressed in HEK 293 cells studied at physiological temperature. Biophys J 1998; 74: 230-241.
41. Lansdell KA, Fraser S, Gillard NP, et al: Effects of cisapride on the cardiac action potential recorded in sheep Purkinje fibres. Br J Pharmacol 1999; 126: 215P.
42. 4-receptor agonists, cisapride, mosapride citrate, and zacopride, on cardiac action potentials in guinea pig isolated papillary muscles. J Cardiovasc Pharmacol 1997; 29: 670-675.
43. Potet F, Bouyssou T, Escande D, et al: Gastrointestinal prokinetic drugs have different affinity for the human cardiac human ether-a-gogo K(+) channel. J Pharmacol Exp Ther 2001; 299: 1007-1012.
44. Walker BD, Singleton CB, Bursill JA, et al: Inhibition of the human ether-a-go-go-related gene (HERG) potassium channel by cisapride: affinity for open and inactivated states. Br J Pharmacol 1999; 128: 444-450.
45. Demolis JL, Kubitza D, Tenneze L, et al: Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects. Clin Pharmacol Ther 2000; 68: 658-666.
46. Noel GJ, Natarajan J, Chien S, et al: Effects of three fluoroquinolones on QT interval in healthy adults after single doses. Clin Pharmacol Ther 2003; 73: 292-303.
47. Malik M, Hnatkova K, Batchvarov V, et al: Sample size, power calculations, and their implications for the cost of thorough studies of drug induced QT interval prolongation. Pacing Clin Electrophysiol 2004; 27: 1659-1669.
48. Berger E, Patel K, Anwar S, et al: Investigation of the effects of physiological and vasodilation-induced autonomic activation on the QTc interval in healthy male subjects. Br J Clin Pharmacol 2005; 60: 17-23.
49. 4 receptors in the pig. Naunyn Schmiedebergs Arch Pharmacol 1992; 346: 629-636.
50. 4 receptor. Br J Pharmacol 1990; 100: 665-667.
51. 4 receptor mediating tachycardia in piglet isolated right atrium. Br J Pharmacol 1993; 110: 1023-1030.
52. Sullivan JT, Lettieri JT, Liu P, et al: The influence of age and gender on the pharmacokinetics of moxifloxacin. Clin Pharmacokinet 2001; 40(suppl 1): 11-18.
53. Lubasch A, Keller I, Borner K, et al: Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers. Antimicrob Agents Chemother 2000; 44: 2600-2603.
54. Stass H, Kubitza D, Moller JG, et al: Influence of activated charcoal on the pharmacokinetics of moxifloxacin following intravenous and oral administration of a 400 mg single dose to healthy males. Br J Clin Pharmacol 2005; 59: 536-541.